WINTON GROUP Ltd Purchases New Stake in AtriCure, Inc. $ATRC

WINTON GROUP Ltd acquired a new position in AtriCure, Inc. (NASDAQ:ATRC) in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund acquired 35,800 shares of the medical device company’s stock, valued at approximately $1,002,000.

Other institutional investors and hedge funds also recently modified their holdings of the company. Smartleaf Asset Management LLC raised its holdings in shares of AtriCure by 59.8% during the fourth quarter. Smartleaf Asset Management LLC now owns 1,146 shares of the medical device company’s stock worth $46,000 after purchasing an additional 429 shares during the period. Scotia Capital Inc. boosted its holdings in shares of AtriCure by 1.2% in the 3rd quarter. Scotia Capital Inc. now owns 37,677 shares of the medical device company’s stock valued at $1,328,000 after buying an additional 457 shares during the period. ProShare Advisors LLC grew its position in shares of AtriCure by 6.6% during the 4th quarter. ProShare Advisors LLC now owns 8,819 shares of the medical device company’s stock valued at $349,000 after buying an additional 543 shares during the last quarter. Captrust Financial Advisors grew its position in shares of AtriCure by 7.9% during the 4th quarter. Captrust Financial Advisors now owns 7,944 shares of the medical device company’s stock valued at $314,000 after buying an additional 579 shares during the last quarter. Finally, Mackenzie Financial Corp raised its stake in AtriCure by 5.3% during the fourth quarter. Mackenzie Financial Corp now owns 13,597 shares of the medical device company’s stock worth $545,000 after acquiring an additional 683 shares during the period. 99.11% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling at AtriCure

In related news, insider Karl Dahlquist sold 9,370 shares of AtriCure stock in a transaction on Monday, August 24th. The stock was sold at an average price of $48.89, for a total value of $458,099.30. Following the transaction, the insider directly owned 87,319 shares in the company, valued at $4,269,025.91. The trade was a 9.69% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, Director Maggie Yuen sold 3,500 shares of the company’s stock in a transaction on Wednesday, August 5th. The shares were sold at an average price of $38.42, for a total value of $134,470.00. Following the sale, the director directly owned 14,015 shares of the company’s stock, valued at approximately $538,456.30. This represents a 19.98% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last quarter, insiders sold 65,036 shares of company stock worth $2,758,687. 4.00% of the stock is owned by insiders.

AtriCure Price Performance

Shares of NASDAQ ATRC opened at $54.54 on Monday. AtriCure, Inc. has a twelve month low of $25.36 and a twelve month high of $55.72. The company has a current ratio of 4.22, a quick ratio of 3.19 and a debt-to-equity ratio of 0.14. The company has a market capitalization of $2.77 billion, a price-to-earnings ratio of 259.73 and a beta of 1.26. The firm has a 50-day moving average of $42.41 and a two-hundred day moving average of $33.56.

AtriCure (NASDAQ:ATRC) last announced its quarterly earnings data on Thursday, July 23rd. The medical device company reported $0.18 earnings per share (EPS) for the quarter. The company had revenue of $153.60 million for the quarter, compared to analysts’ expectations of $151.80 million. AtriCure had a net margin of 1.85% and a return on equity of 2.34%. During the same quarter in the previous year, the company posted ($0.13) EPS. AtriCure has set its FY 2026 guidance at 0.240-0.320 EPS. As a group, analysts expect that AtriCure, Inc. will post 0.29 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of equities analysts have commented on ATRC shares. UBS Group decreased their target price on AtriCure from $55.00 to $50.00 and set a “buy” rating for the company in a research note on Tuesday, July 28th. Raymond James Financial set a $52.00 price target on AtriCure in a report on Tuesday, July 21st. Weiss Ratings upgraded AtriCure from a “sell (d+)” rating to a “hold (c-)” rating in a research report on Wednesday, August 19th. Needham & Company LLC upped their price objective on AtriCure from $45.00 to $64.00 and gave the stock a “buy” rating in a research note on Wednesday, September 2nd. Finally, Zacks Research lowered AtriCure from a “strong-buy” rating to a “hold” rating in a research report on Monday, August 24th. One research analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating and four have issued a Hold rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $52.00.

AtriCure Company Profile

AtriCure, Inc (NASDAQ: ATRC) is a medical device company focused on the treatment of atrial fibrillation (AF) and related conditions. The company develops, manufactures and sells surgical and minimally invasive technologies designed to restore normal heart rhythm and reduce the risk of stroke associated with AF.

Its product portfolio includes the AtriClip system for excluding the left atrial appendage, the Isolator and Synergy systems for surgical ablation, and the cryoICE system, which uses cryothermal energy in cardiac procedures.